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Abstract
Using transcriptomic and metabolomic measurements from the NCI60 cell line panel, together with a novel approach to
integration of molecular profile data, we show that the biochemical pathways associated with tumour cell chemosensitivity
to platinum-based drugs are highly coincident, i.e. they describe a consensus phenotype. Direct integration of metabolome
and transcriptome data at the point of pathway analysis improved the detection of consensus pathways by 76%, and
revealed associations between platinum sensitivity and several metabolic pathways that were not visible from
transcriptome analysis alone. These pathways included the TCA cycle and pyruvate metabolism, lipoprotein uptake and
nucleotide synthesis by both salvage and de novo pathways. Extending the approach across a wide panel of
chemotherapeutics, we confirmed the specificity of the metabolic pathway associations to platinum sensitivity. We
conclude that metabolic phenotyping could play a role in predicting response to platinum chemotherapy and that
consensus-phenotype integration of molecular profiling data is a powerful and versatile tool for both biomarker discovery
and for exploring the complex relationships between biological pathways and drug response.
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Introduction
In the quest to understand complex biological systems at
multiple levels of biological organization, the need arises to
combine knowledge from experiments of different types to create a
full picture of a system’s behavior. Modern molecular profiling
(‘‘omics’’) methods, such as transcriptomics, proteomics and
metabolomics allow one to build up a global picture of system
characteristics, and to search for interactions and coordinated
behavior between the different levels. While each level can be
studied separately, greater statistical and explanatory power can be
gained by integrating this knowledge into a single coherent model
of the system. This is currently one of the greatest challenges in
systems biology.
Inter-omic data integration can be performed at different levels
[1], the simplest of which is conceptual integration. At this level,
each omics data set is analysed separately and a coherent
biological rationale is constructed which explains phenomena
observed in the separate molecular profiles. For example, changes
in levels of both enzyme transcripts and metabolites from the same
pathway could be explained by the hypothesis of differential
regulation of that pathway. However this subjective approach can
lead to plausible biological explanations that arise through
spurious statistical associations and conversely some potentially
novel mechanisms may be overlooked. The statistical level of
integration is more objective. In this approach, links between data
sets are made using rigorous statistical procedures such as
correlation, regression or more sophisticated techniques. To date,
much inter-omic data integration has been performed at the
conceptual level [2,3,4] while various methods have been
proposed and demonstrated for statistical integration [5,6,7,8,9].
Many researchers have found that interpretation of omics data
at the level of individual molecular entities can be difficult and
have opted for an analysis at the pathway or functional level [10].
This is mainly because particular changes in biochemical
pathways, associated with phenotypic conditions such as disease
can often arise from a range of different alterations in a pathway.
A common method for performing pathway-level analysis on
single omic data is over-representation (OR) analysis [11,12], in
which a set of molecular elements (e.g. genes) that are differentially
expressed or correlated with the phenotype of interest are first
selected. The set is then compared against molecular sets defined a
priori (e.g. genes in established pathways) to identify those sets that
show greater overlap with the phenotype-associated genes than
would be expected by chance. The final list of significantly over-
represented or ‘enriched’ sets/pathways is used to aid biological
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Metabolite Set Enrichment Analysis (MSEA) [13] and other
metabolite over-representation techniques [14] have also been
developed. In this work we contrast the application of the OR
analysis approach to transcript and metabolite data individually to
the alternative of considering them simultaneously, using estab-
lished pathways to guide an integrated analysis of the two data sets.
In addition to the inter-omic integration of metabolomic and
transcriptomic data, our approach involves a further type of data
integration that we call consensus-phenotype integration. In this
approach, several examples of the same phenotype, achieved in
different ways, are used within the experimental design. For
example, one may study a particular mechanism of toxicity via the
use of different chemical treatments that have a similar mode of
action. One can thus identify features that are central to the
phenotype in question across different types of ‘‘omics’’ data, as
opposed to features that are specific to a single instance of the
phenotype being studied.
In this work, we aim to elucidate mechanisms of drug
sensitivity through the use of inter-omic statistical data
integration using drug sensitivity, transcriptomic and metabo-
lomic data from the NCI60 cell line panel [15]. The NCI60 is a
panel of tumor derived cell lines corresponding to diverse tissue
types, which has been subject to extensive molecular phenotypic
and pharmacological characterization. We used baseline
(untreated) metabolic and transcriptional profiles readily
available for 58 lines as well as growth inhibition data from
an array of 118 drugs [15,16]. We correlate growth inhibition to
the molecular profiles to identify pathways related to drug
sensitivity. We first focus on platinum sensitivity as it is a well-
defined phenotype, linked to a well-investigated mode of action
that has important clinical implications. Many chemotherapeu-
tic regimes are based on platinum compounds, and resistance to
these drugs is a major obstacle in successful treatment of some
cancers. The mechanisms that cause variation in response to
therapy are not well understood, and the ability to predict
sensitivity from a baseline profile of the tumor would help to
improve therapy selection and thereby potentially reduce
patient morbidity and mortality. We then expand our analysis
to a larger set of 118 drugs to investigate whether the method is
able to associate drugs with similar modes of action. We show
that statistical integration conducted through a joint analysis of
the data gives specific advantages in terms of sensitivity and
confidence of pathway associations.
Results
Figure 1 shows a schematic overview of our data analysis
strategy. Whole genome gene expression (transcriptomic), meta-
bolomic, and drug sensitivity data were obtained for the NCI60
tumor cell line panel. The transcriptomics data was derived using
the U133 Affymetrix chip; in total 44928 probesets were
measured, equating to 17150 gene products mapping to distinct
UniProt identifiers, each measured across 58 cell lines [17]. The
metabolomic data consisted of measurements of the total
intracellular abundance of 154 uniquely identified metabolites
across all 58 cell lines [18], including lipid compounds (e.g.
cholesterol), glycolytic intermediates (e.g. glucose-6-phosphate),
nucleic acid metabolites (e.g. adenine, uracil, hypoxanthine) and
amino acids (e.g. glutamate, taurine). The full list along with our
assigned KEGG IDs can be obtained in Table S4. We used drug
sensitivity data (GI50 values indicating the concentration of the
drug which inhibited cell growth by 50%) [15,16] initially for four
platinum-based chemotherapeutics, cisplatin, carboplatin, tetra-
platin and iproplatin. Data for a fifth platinum drug (diaminocy-
clohexyl-Pt(II)) was available, and was used at a later stage as a test
compound to validate our findings.
Identifying pathways significantly associated to platinum
sensitivity
For each drug we ranked all probe sets by their absolute Pearson
correlation (|r|) to the 2log(GI50) values across all cell lines.
Setting the false discovery rate (FDR) [19] at 60% we then selected
genes considered to be significantly associated to chemosensitivity.
A high FDR was tolerated at this stage of the analysis to ensure
that subsequent pathway analysis was adequately powered.
Repeating this process for the metabolite data we obtained
separate panels of genes and metabolites that were deemed to be
associated with the sensitivity to each drug (see Table S1). In total
3, 33, 37 and 92 metabolites and 915, 1620, 5035 & 6533 genes
were identified as associated with sensitivity to carboplatin,
cisplain, iproplatin and tetraplatin treatment respectively.
To assess which pathways characterized the drug sensitivity
phenotype we then performed OR analysis with pathways from
the ConsensusPathDB [20]. The ConsensusPathDB collates
pathways from several public databases of protein interactions,
signaling and metabolic pathways as well as gene regulation in
humans. We restricted our analysis to sources covering
biochemical reactions: KEGG [21], Reactome [22], Netpath
(http://www.netpath.org), Biocarta (http://www.biocarta.com),
HumanCyc [23] and the pathway interaction database (PID)
[24]. The use of multiple databases reduces bias by enhancing
coverage. At the time of analysis the ConsensusPathDB contained
1875 pathways from the selected sources, of which 1651 contain
at least one gene and 581 contain at least one metabolite
measured in the NCI60 data (excluding the highly prevalent
‘currency’ metabolites phosphate, diphosphate and NADP+). OR
analysis of the phenotype-associated gene panels indicated that
63, 74, 233 and 242 pathways were associated with cisplatin,
carboplatin, iproplatin and tetraplatin sensitivity respectively
(p,0.05). The equivalent analysis for metabolite panels indicated
that 24, 13, 4, & 5 pathways were associated with these
phenotypes.
Author Summary
Resistance to chemotherapy drugs in cancer sufferers is
very common. Using a panel of 59 cell lines obtained from
different types of cancer we study the links between the
genes and metabolites measured in these cells and the
resistance the cells show to common cancer drugs
containing platinum. In order to combine the information
given by the genes and metabolites we introduce a new
pathway-based approach, which allows us to explore
synergy between the different types of data. We then
extend the procedure to look at a wider panel of drugs
and show that the pathways we found were associated
with platinum are not just the pathways which are
frequently selected for a large number of drugs. Given
the increasing use of multiple sets of measurements
(genes, metabolites, proteins etc.) in biological studies, we
demonstrate a powerful, yet straightforward method for
dealing with the resulting large datasets and integrating
their knowledge. We believe that this work could
contribute to developing a personalised medicine ap-
proach to treating tumours, where the genetic and
metabolic changes in the tumour are measured and then
used for prediction of the optimal treatment regime.
Consensus-Phenotype Integration
PLoS Computational Biology | www.ploscompbiol.org 2 March 2011 | Volume 7 | Issue 3 | e1001113Consensus pathway and inter-omic integration
To highlight pathways relevant to general platinum sensitivity,
as opposed to particular platinum compounds, we looked for
pathways that were associated with more than one drug response
phenotype (‘consensus-phenotype integration’; Figure 2 A & B).
Within the gene transcript analysis (Figure 2A), the drugs
appeared to divide into two pairs that shared many pathways in
common. Iproplatin and tetraplatin were most similar, sharing 143
(133+4+4+2) of the 330 (75+5+5+4+143+92+3+1+2), ie. 43% of
the pathways associated with either drug (Figure 2A). Carboplatin
and cisplatin also show a high level of similarity (32 of 103
pathways, 31%). In the metabolic analysis (Figure 2B) the
similarity between iproplatin and tetraplatin was much lower,
while carboplatin and cisplatin retained a high level of similarity
with 7 of the 30 pathways being shared (23%). The gene analysis
highlights many more pathways than metabolite analysis due to
both the higher number of pathways with sufficient numbers of
quantified transcripts and the limited number of quantified and
identified metabolites.
We next combined the transcriptomic and metabolomic data
into a joint inter-omic OR analysis (Figure 2C) by estimating the
joint probability of association of each pathway with the drug
sensitivity phenotype assuming independence between the prob-
ability of association from the gene and metabolite data separately
(see Methods). 35 pathways were found to be significant for at least
one drug in the joint analysis that did not feature in either of the
separate analyses of gene expression or metabolite levels. To
confirm the significance of the increase in pathway detection after
integration of the metabolic and transcriptomic data, we estimated
the null distribution of the joint analysis probabilities by permuting
the gene analysis pathway probabilities relative to the metabolite
analysis pathway probabilities. For carboplatin only 3 of the 100
Figure 1. Consensus-phenotype integration of transcript and metabolite data: a schematic of the study design.
doi:10.1371/journal.pcbi.1001113.g001
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cisplatin no permutations produced as many pathways as the real
data. However, for iproplatin and tetraplatin, the number of
pathways detected was not significantly enhanced by the joint OR
analysis, suggesting that the combined analysis may be most
advantageous when the numbers of significantly associated genes
or metabolites are relatively low.
To examine the significance of the numbers of pathways in the
joint OR analysis that were commonly associated to the effect of
multiple drug treatments, two null models were generated. Null
model I assumed that genes and metabolites identified as
significantly associated to a phenotype were randomly selected
whereas null model II correspondingly assumed that pathways are
selected randomly. Table 1 summarizes the pathway coincidence
between the output of joint OR analysis across the four platinum
drugs for these two null models compared to the real data and
reports the associated FDR in each analysis. We observed that by
setting our criterion of significant association between a pathway
and platinum sensitivity at requiring a majority of the drugs to be
associated with that pathway (i.e. at least 3/4) we achieved
acceptable FDRs of 0.2% (null model I) and 16.9% (null model II,
the most extreme scenario).
Using the majority overlap criterion we compared the number
of pathways consistently associated with platinum sensitivity
between the individual and joint analyses (Figure 2D). The joint
OR analysis identified all pathways highlighted by the individual –
omic OR analyses combined (17 in total), but also indicated a
further 13 pathways that were consistently associated (+76%). No
pathways were found to be common between both the separate
gene and metabolite analyses.
Overall 30 pathways met the majority criterion of association
with sensitivity at least 3 platinum drugs and hence general
platinum cytotoxicity (Table 2; Figure 2C & D). All the databases
used to compile the ConsensusPathDB contributed pathways to
the final selected consensus pathways, highlighting the value of the
ConsensusPathDB strategy in pathway analysis. While this subset
of pathways included those with established relationships to
platinum sensitivity and general chemosensitivity, such as DNA
repair and Akt regulation of nuclear transcription, there were also
several pathways related to metabolic processes not previously
Figure 2. Consensus-phenotype and inter-omic integration at the pathway level. The numbers of common pathways significantly over-
represented for each compound are shown as Venn diagrams. A transcript data, B metabolite data, C inter-omic analysis using both metabolite and
transcript data and D comparison of the three approaches using pathways which are significant for at least three drugs. (All Venn diagrams produced
by Venny [55]).
doi:10.1371/journal.pcbi.1001113.g002
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nucleotide metabolism, fatty acid, triglyceride and lipid metabo-
lism.
The added value of the inter-omic OR analysis prior to
consensus phenotype integration can be more clearly discerned at
the individual pathway level. Figure 3 is a network representation
of the base excision repair (BER) pathway from Reactome and
depicts both the detected entities and the drugs with which each
detected entity is associated. While the majority of entities were
significantly associated to the effect of at least one of the four
platinum agents, there was significant variation in the pattern of
association and no gene or metabolite was significantly associated
to all four treatments. Accordingly the pathway was only
significantly associated to tetraplatin and iproplatin sensitivity
using the transcriptome data alone, and to carboplatin and
cisplatin sensitivity using the metabolite data in isolation. Using the
joint OR analysis the BER pathway was significantly associated to
the sensitivity to all four platinum compounds (Table 2) and the
evidence for association with each drug was increased, due to the
added information from the alternative data type. Of the 12
pathways for which inter-omic OR analysis improved the
consensus between the drugs, 10 refer to metabolic processes.
In order to validate and to test the generalisability of our
findings we then examined GI50 data from a test compound,
diaminocyclohexyl-Pt(II). After conducting the same inter-omic
OR analysis as described previously, we observed that the effects
of this compound on the NCI60 panel was associated with 5 of the
6 pathways common to all 4 other platinum drugs along with a
further 12 pathways from Table 2 and 90% (220/245) of the
pathways associated with diaminocyclohexyl-Pt(II) were Associat-
ed with at least one of the other platinum drugs. In particular there
were 138/152 pathways commonly associated between diamino-
cyclohexyl-Pt(II), iproplatin and tetraplatin sensitivity. Since OR
analysis makes no distinction between positive and negative
molecule/sensitivity correlations, we also examined the direction
of associations between the metabolites detected in the consensus
pathways and the GI50 of all platinum drugs (Table 3). In total, a
panel of 22 metabolites were associated with the consensus
metabolic pathways from analysis of the four training compounds.
While there was variation in the metabolites associated with
specific treatments, where a significant association was observed
the direction of correlation was consistent across the training set.
The GI50 values of our test compound, diaminocyclohexyl-Pt(II),
was significantly correlated to 19/22 metabolites in this panel,
with complete consistency in the direction of association with the
training set data.
Global analysis of chemosensitivity pathways
To explore more broadly the relationships between chemosen-
sitivity and biological pathways across a range of agents, and to
ascertain the specificity of the consensus phenotype analysis for
platinum sensitivity pathways, inter-omic OR analysis was
performed using GI50 data for all 118 compounds available within
the NCI 60 dataset. In total 1262 pathways were significantly
associated with the drug sensitivity of at least one compound, while
82 compounds gave at least one significant pathway. Figure 4
shows the clustered heat-map of the binary association matrix in
which each element is set to one if a pathway is significantly
associated with sensitivity to a given drug and zero otherwise (see
Table S2). Significant clustering of the drugs according to mode of
action is visible. For example the dihhryofolate reductase inhibitor
methotrexate co-clustered with related compounds aminopterin,
trimetrexate, and Baker’s-soluble-antifolate (triazinate) (Figure 4,
blue asterisks); the sensitivities to all four compounds were
associated with 91 common pathways. While one might expect
structural analogues such as these to produce a similar pattern of
sensitivity and hence similar pathway associations, structurally
unrelated compounds that share a common molecular target also
co-clustered in certain instances. One interesting observation was
the similarity in pathway association, reflected by common
membership of a cluster, of several structural analogues, the
anthracycline-based compounds, (doxorubicin, zorubicin, danor-
ubicin hydrochloride and deoxydoxorubicin) with the podophyl-
lotoxin-based etoposide and teniposide (Figure 4, green asterisks).
The four anthracyclines in the cluster share a large proportion of
associated pathways: 63 of the 401 pathways associated with any of
the anthracyclines are commonly associated to the effect of all four
compounds, and of these, 60 are also associated to the
chemosensitivity to either teniposide or etoposide. Etoposide and
its derivatives directly inhibit topoisomerase II activity, followed by
induction of DNA strand breaks and selective cytotoxicity in
tumour cells [25] whereas anthracyclines intercalate DNA,
indirectly inhibiting the progression of topoisomerase II and
blocking replication [26]. Thus, the inter-omic pathway analysis is
apparently able to associate chemosensitivity phenotypes on the
basis of a common pathophysiological link independent of whether
the key molecular targets are affected directly, or indirectly by an
upstream process.
While such mechanistic relationships were readily observable,
the most prominent division between the compounds, visible as the
two largest clusters in Figure 4, appeared to be separating on the
overall frequency of pathways associated with chemosensitivity,
with the top cluster in the diagram possessing on average 2.95
times the number of positive associations of the lower cluster.
While each of the five platinum compounds in the dataset were
most similar in pathway associations to another platinum
compound, they were separated across the two largest clusters
with cisplatin and carboplatin forming one group and tetraplatin,
iroplatin and diaminocyclohexyl-Pt II another. This separation
agreed with the low numbers of common chemosensitivity
pathways between members of these two groups in earlier analyses
(Figure 2). Thus, the clustering structure did not describe
associations common across the platinum compounds, illustrating
the difficulty of using clustering approaches alone to identify
pathways that may determine class-specific chemosensitivity and
the advantages of the consensus phenotype approach.
To assess the specificity of the identified consensus platinum-
sensitivity pathways we compared these to the most frequently
associated pathways in the global inter-omic OR analysis (Table
S2). Of the 54 (top 50 including ties) most frequently associated
pathways (Table S3), just seven intersect with pathways identified
Table 1. Null models I and II.
Number of pathways common to
exactly n drugs and FDR
Number of drugs, n 123 4
Real data
(inter-omic analysis)
251 182 24 6
Null model I 161.8 6.6 0.06 0.0
Cumulative false discovery rate 36.4% 3.2% 0.2% 0.0%
Null model II 539.3 81.2 5.0 0.1
Cumulative false discovery rate 40.7% 16.9% ,0.1%
The numbers of pathways associated with exactly n drugs for each of the null
models and in real data.
doi:10.1371/journal.pcbi.1001113.t001
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Effective size of pathway in
terms of… Number of drugs with this pathway over-represented in…
Pathway and source database genes metabolites Inter-omic analysis gene analysis metabolite analysis
Metabolic Pathways
22 2 3 2 0
Triacylglyceride Biosynthesis Reactome 29 3 4 3 0
Purine metabolism Reactome 82 16 3 2 1
Purine metabolism - Homo sapiens
(human) KEGG
412 19 3 2 1
DNA Repair Reactome 144 5 3 1 1
Hormone-sensitive lipase
(HSL)-mediated triacylglycerol
hydrolysis Reactome
23 2 3 1 2
Lipid and lipoprotein
metabolism Reactome
243 9 3 2 0
De novo biosynthesis of pyrimidine
deoxyribonucleotides HumanCyc
17 1 3 1 0
Salvage pathways of purine and
pyrimidine nucleotides HumanCyc
45 9 3 1 0
Phosphatidylcholine biosynthesis
pathway BioCarta
61 3 2 0
Base Excision Repair Reactome 27 3 4 2 2
Nucleotide metabolism Reactome 137 27 3 2 1
Pyruvate metabolism and TCA cycle Reactome 52 6 3 3 0
Reversible phosphorolysis of pyrimidine
nucleosides Reactome
23 3 0 3
Phospholipid biosynthesis II HumanCyc 57 4 3 3 0
Non-Metabolic pathways
Signaling in Immune system Reactome 467 1 3 2 0
Hemostasis Reactome 390 1 3 2 0
Rho GTPase cycle Reactome 265 0 4 4 N/A
lck and fyn tyrosine kinases in initiation
of tcr activation BioCarta
18 0 3 3 N/A
AKT phosphorylates targets in
the nucleus Reactome
31 0 3 3 N/A
TCR signaling in naı ¨ve CD8+ T cells PID 107 0 3 3 N/A
TCR NetPath 267 0 4 4 N/A
BCR NetPath 316 0 3 3 N/A
Immunoregulatory interactions between a
Lymphoid and a non-Lymphoid cell Reactome
138 0 3 3 N/A
amb2 Integrin signaling PID 98 0 3 3 N/A
Apoptotic dna-fragmentation and tissue
homeostasis BioCarta
17 0 4 4 N/A
Apoptotic cleavage of cell adhesion
proteins Reactome
16 0 3 3 N/A
Notch receptor binds with a ligand Reactome 20 0 3 3 N/A
Receptor-ligand binding initiates the
second proteolytic cleavage of
Notch receptor Reactome
22 0 3 3 N/A
Integrin cell surface interactions Reactome 171 0 4 4 N.A
Pathways shown are those significantly over-represented in at least 3 drug lists for the inter-omic analysis. N/A indicates no quantified metabolites were present in the
pathway. Rows shown in bold are those where the inter-omic analysis means that the pathway is significantly associated with chemosensitivity to more drugs than the
individual analyses combined. The pathways are split into two classes, metabolic and non-metabolic and then ordered so that the pathways with improved detection in
the inter-omic analysis are at the top of the table.
doi:10.1371/journal.pcbi.1001113.t002
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regulatory processes (‘‘T-cell receptor’’ – Netpath; ‘‘B-Cell
receptor’’ – Netpath; ‘‘Rho GTPase cycle’’ – Reactome; ‘‘lCK
and FYN tyrosine kinases in initiation of TCR activation’’ –
BioCarta; ‘‘AMB2 integrin signalling’’ – PID; ‘‘Immunoregulatory
interactions between a Lymphoid and a non-Lymphoid cell’’ –
Reactome; and ‘‘TCR signalling in naive CD8 T cells’’ – PID).
Hence the remaining 23/30 consensus platinum-sensitivity
pathways, dominated by metabolic processes, are not associated
with sensitivity to a wide range of chemotherapeutic agents and
are more likely to be specific to platinum sensitivity.
Discussion
Our results show that an inter-omic, consensus phenotype
approach to integration of molecular profiles can reveal a cellular
metabolic phenotype robustly associated with platinum chemosen-
sitivity across the NCI-60 cell line panel. Many of the specific
aspects of this phenotype are consistent with the perturbations
described across many studies of tumour cell metabolism, and
severalof these have been associated withthe development, or likely
acquisition, of drug resistance phenotypes. The classic hallmark of
tumour cell metabolism is the Warburg effect: an increase in glucose
uptake and glycolysis to lactate even in normal oxygen conditions.
In addition to the Warburg effect tumour cells are frequently
reported as exhibiting higher rates of glutaminolysis, fatty acid and
lipid metabolism, and nucleotide synthesis [27]. Our observations
from the NCI-60 molecular profiles suggest a positive correlation
between all of these phenotypes and platinum chemosensitivity.
Figure 5 summarises some of the key correlations observed
between gene transcription, metabolite levels and platinum
sensitivity from the consensus pathways indicated by our analysis.
The relatively higher levels of citrate and phosphoenolpyruvate
(PEP), observed in more sensitive cell lines (Figure 5A), are
consistent with low TCA cycle activity (via product inhibition) and
increased diversion of glycolytic intermediates into anabolic
pathways such as the pentose phosphate which feeds nucleotide
synthesis [28]. Under these conditions tumour cells increase the
uptake of glutamine and its conversion to oxaloacetate via
glutamate and 2-oxoglutarate (2-OG) in order to replace TCA
cycle intermediates and NADPH [29]. Both glutamate and 2-OG
levels were also higher in more sensitive cell lines. Thus more
‘Warburg–like’ cells appear more sensitive to platinum treatment
than less metabolically transformed lines. The selection of TCA
cycle and pyruvate metabolism as a sensitivity pathway in our
analysis is likely to reflect these associations.
Figure 3. Base Excision Repair Pathway (Reactome). The Pathway diagram was generated using ConsensusPathDB [20]. All quantified
metabolites and transcripts are marked and the drugs with which they appeared associated are shown. A solid line indicates a substrate or product
(or protein participating in a protein complex) and a dotted line shows an enzymatic link.
doi:10.1371/journal.pcbi.1001113.g003
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intermediates could be exploited in platinum chemotherapy; for
example the clinically-relevant glycolysis inhibitor 2-deoxy-glucose
(2-DG) has been shown to enhance cisplatin cytotoxicity in head
and neck cancer cells [30]. Interestingly, this synergy appeared to
be mediated in part via oxidative stress, a process that would lead
to DNA lesions (e.g. 8-oxo-29-deoxyguanosine) requiring base
excision repair (BER) which was one of the key consensus
sensitivity pathways selected by our analysis (Figure 3). While it is
clear that nucleotide excision repair (NER) capacity is linked to
cisplatin resistance [31,32,33]; it is becoming evident that BER is
also important in the effect of cisplatin derived drugs [34]. Cross-
linking of DNA via platinum derived drugs can increase the
production of free radicals by disrupting the cellular redox balance
[35]. We suggest that the association of the BER pathway with
four platinum drugs observed in the present study is related to
increased ROS production and not adduct formation (repaired by
NER). Intracellular levels of ROS seem vital to the cytotoxic effect
of the platinum derived drugs, further evidenced by the fact that
oxaliplatin (a later generation of Pt drug) is highly cytotoxic but
forms less platinum-DNA adducts compared to equal amounts of
cisplatin [35].
A particularly high degree of coordination between gene
transcript and metabolite levels was observed in nucleotide
metabolism, revealing a robust association between increased
nucleotide synthesis, both de novo and via recovery of catabolic
intermediates, and tumour cell Pt sensitivity (Figure 5B). For
example, in the de novo pathway, we observed a positive correlation
between levels of dUTP (a precursor to dTMP), expression of
dUTP pyrophosphatase (DUT r=0.38), expression of thymidylate
synthase (TYSY r=0.27) and platinum sensitivity. dUTP has to be
hydrolysed to dUMP by DUT to prevent the incorporation of
uracils into DNA and suppression of DUT has been shown to
sensitize cells to other chemotherapeutics such as pyrimidine anti-
metabolites [36].
Increased expression of nucleotide salvage pathway enzymes
(e.g. uracil phosphoribosyl transferase or UPP (r=0.20), hypo-
xanthine-guanine phosphoribosyl transferase or HPRT, r=0.27)
in sensitive cell lines was accompanied by decreases in several
intermediates of purine and pyrimidine catabolism (namely
guanine, guanosine, hypoxanthine, inosine, uracil, uridine and
urea) and increase in CMP, the nucleotide product of HPRT.
Kowalski et al. [37] have shown clear links between inactivation of
salvage pathway enzymes such as HGPRT or loss of feedback
inhibition to AMP and GMP de novo synthesis and cisplatin
resistance in yeast. Interestingly in the same study the addition of
low concentrations of extracellular purines also abolished cisplatin
cytotoxicity; thus the metabolome may have a causal influence on
platinum sensitivity and not just represent epiphenomena that is a
passive consequence of aberrant cell division.
Our pathway analysis also predicts that lipid metabolism has a
direct impact on chemosensitivity. We observed lower cholesterol,
glycerol, and hexadecanoic acid (palmitate) in more sensitive cell
lines, together with negative correlations between expression of
apolipoprotein E (APOE; mean R=20.21), LDL receptor
(LDLR; mean R=20.27) and platinum sensitivity (Figure 5C).
All these observations are consistent with a hypothesis that
increased uptake of lipoproteins and constituent triglycerides, fatty
Table 3. Metabolites involved in the pathways from Table 2, showing the direction of association (if above the FDR cutoff) and r,
the correlation coefficient to the 2log(GI50) values.
Carboplatin Cisplatin Iproplatin Tetraplatin Diaminocyclohexyl-Pt II
2-oxoglutarate 0.18 q 0.26 0.20 0.12 q 0.16
Adenine 0.01 20.01 0.13 q 0.21 q 0.15
b-alanine 20.13 20.04 0.05 q 0.28 q 0.23
Citrate 0.00 0.01 0.23 q 0.21 q 0.19
CMP 20.04 20.04 0.15 q 0.22 q 0.21
dUTP 0.20 q 0.25 0.20 q 0.24 q 0.25
L-glutamate 0.00 0.09 0.02 q 0.23 q 0.22
Phosphoenol-pyruvate 0.00 0.09 q 0.26 q 0.33 q 0.30
S-adenosyl-L-methionine 0.02 20.01 0.20 q 0.27 q 0.20
Taurine 20.14 20.03 0.11 q 0.45 q 0.35
Cholesterol 20.16 Q 20.25 Q 20.35 Q 20.37 Q 20.38
Deoxyuridine 0.03 0.02 20.02 Q 20.21 Q 20.18
Glycerol 20.21 Q 20.27 Q 20.43 Q 20.38 Q 20.36
Guanine 20.02 20.04 20.15 Q 20.20 Q 20.18
Guanosine 20.06 20.16 Q 20.30 Q 20.24 Q 20.30
Hexadecanoic Acid 0.03 20.09 Q 20.26 Q 20.22 Q 20.27
Hypoxanthine Q 20.36 Q 20.36 20.13 20.05 20.04
Inosine 20.21 Q 20.25 20.07 20.05 20.10
Uracil 20.19 Q 20.25 Q 20.28 Q 20.19 Q 20.21
Urea 20.14 Q 20.25 Q 20.31 Q 20.36 Q 20.37
Uridine Q 20.38 Q 20.34 20.17 Q 20.18 Q 20.20
Xanthine Q 20.32 Q 20.25 20.13 20.07 20.02
doi:10.1371/journal.pcbi.1001113.t003
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phenomenon previously shown in drug resistant leukemic cell
lines [38]. A related pathway highlighted as associated with
sensitivity was phosphatidylcholine biosynthesis. We observed a
positive correlation between choline kinase (CK, r=20.28,
correlation to 2log(GI50)) expression and resistance to platinum.
Recent work by Shah et al. [39] in breast cancer cells have shown
that CK regulates pro-survival MAPk and PI3K/Akt signaling via
phosphatidic acid, and that overexpression leads to drug
resistance.
While previous pathway analysis was conducted on gene
expression profiles alone from the NCI60 dataset [40], the use of
correlation analysis and the combination of metabolite and gene
transcription measures in our study provides an unprecedented level
of detail into the contribution of metabolic pathways to drug
sensitivity. Using gene set enrichment analysis (GSEA), Reidel et al.
[40] suggested that, in addition to a number of cell signaling and
survival networks, methionine metabolism may contribute to
chemotherapeutic resistance to multiple agents, while fatty acid and
b-alanine metabolism were specifically associated with platinum-
resistance. In the context of fatty acid metabolism we show here that
lipid uptake and processing may in fact be the driving factor in this
association. It is also interesting to note that although we did not
observe over-representation of b-alanine and methionine metabolic
pathways, both b-alanine and S-adenosylmethionine levels were
significantly positively correlated to platinum sensitivity, adding
functional evidence in support of these earlier findings.
At present, our study is one of very few that presents a strategy
for simultaneous interpretation of gene expression data, metabolic
profiles and physiological endpoints using biological pathway
analysis, and has several advantages over other approaches.
Multivariate analysis using pattern recognition algorithms such as
PCA, [41], PLS [42] and Kohonen Networks (Self-Organising
maps) [43], have been shown to be useful in revealing novel
associations between ‘‘-omics’’ datasets, but fail to take into
account prior biological knowledge relevant to the phenomenon at
hand - a feature which is clearly present in pathway-based
techniques. Gene and metabolite coregulation at the pathway level
has been previously studied using OR analysis [44,45]. Transcripts
significantly correlated to metabolite levels were examined for
over-representation of Gene Ontology terms [46] or pathways
(defined by MapMan BINS). Bradley and Gibons’ work reveals a
degree of coordination present between transcriptional and
metabolic measurements at a pathway level, a necessary
prerequisite for our approach to be successful. Importantly none
of these examples use a function physiological endpoint (cytotox-
icity) as driver in pathway selection, leading to a consensus
phenotype description of the phenomenon of interest. We show
here that such an approach is critical in reducing false positive
selection of pathways.
All OR techniques share the limitation that they rely on a
database containing pre-defined pathways, and therefore cannot
identify novel pathways or functional modules. In this work we
have tried to overcome this limitation somewhat through
deconstructing the pathways which were significantly associated
and then functionally interpreting the elements of the pathways
which showed significant associations (Figure 5). However, even
this requires that the elements of the process are sufficiently
grouped in existing pathways to allow for those pathways to be
significantly associated.
Figure 4. Clustering drugs according to the pathways significantly correlated to sensitivity. Red and blue indicates a pathway which is or
is not significant in the inter-omic analysis. A significance level of p,0.05 was used for each pathway. Clustering was performed using complete
linkage and the Hamming distance metric. Pathways not associated with any drug have been omitted from the figure. Red asterisks indicate platinum
drugs, blue asterisks indicate antifolates and green asterisks indicate anthracycline-based drugs.
doi:10.1371/journal.pcbi.1001113.g004
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pathway analysis presented in our study, could assist the
development of anti-resistance chemotherapeutic strategies, and
better individualization of treatment, i.e. personalized medicine.
Using gene expression models (GEMs) based on cytotoxicity in the
NCI-60 panel, Williams et al. [47] were able to stratify tumour
response and/or patient survival in seven independent cohorts of
patients with breast, bladder and ovarian cancer. Crucially, the in
vitro derived GEMs outperformed those derived directly from in
vivo data. Recently it has also been shown that pre-treatment
metabolic profiles can be used to predict the metabolic fate or
effect of drugs in rodents [48], healthy humans [49,50] and breast
cancer patients [51]. Given that the metabolic phenotype of
cancer is already the basis of imaging techniques such as FDG-
PET that are currently used to detect early responses to therapy,
there is potentially great value in combing such pharmaco-
metabonomic studies with other characterization of the patient or
tumour genome and it is our belief that the integration of
molecular profile data yields more than the sum of its parts. It
remains to be seen if the combination of ‘‘-omics’’ data provides a
competitive advantage over targeted biomarker studies for
prognosis and prediction of drug response in oncology. It remains
to be seen if the combination of ‘‘-omics’’ data provides a
competitive advantage over targeted biomarker studies for
prognosis and prediction of drug response in oncology. Several
major challenges to such approaches and translation from in vitro
studies, in particular tumour heterogeneity, require further study.
However, irrespective of biomarker development, the knowledge
that chemotherapeutic sensitivity is in part determined by the
metabolic phenotype suggests that metabolic enzymes may be
potential targets in oncology for both drug naive and chemore-
sistant patients.
Methods
NCI60 and pathway data
The NCI60 data was downloaded from http://dtp.nci.nih.gov/
mtargets/download.html on 27th August 2008. For this work
three datasets were used: metabolite levels, gene expression levels
and drug sensitivities. The metabolite data consists of measure-
ments of 352 metabolites, 154 identified, across 58 cell lines,
performed by Metabolon Inc. [52]. The transcriptomics data was
obtained using the U133 Affymetrix chip by Genelogic [17].
44928 probesets were measured, equating to 17150 genes
mapping to distinct UniProt identifiers, measured across the same
58 cell lines. The drug resistance data was selected from the 118
‘mechanism of action’ drugs data [15,16]. Each compound was
profiled in between 2 and 1176 independent experiments in a 48-
Figure 5. Processes associated with platinum sensitivity. Three processes associated with platinum sensitivity, the arrows indicate the
direction of correlation to the 2log(GI50) values for that gene or metabolite. A Energy metabolism. B Nucleotide de novo synthesis and salvage. C
Lipid uptake.
doi:10.1371/journal.pcbi.1001113.g005
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where GI50 is the dosage of the drug which inhibits the growth of
the cells by 50%. . GI50 values were averaged across the replicates
for each cell line, thus increasing the robustness of the primary
phenotypic endpoint.
Pathways were derived from the ConsensusPathDB [20] which
assimilates pathways from a range of public databases (see Results).
Gene IDs are mapped to UniProt [53] protein IDs. For
metabolites, where available KEGG [21] compound IDs were
used, else, ChEBI [54] IDs were used.
Construction of gene/metabolite lists and
over-representation analysis
Pearson correlations were calculated between all transcript/
metabolite levels and 2log(GI50) values for each drug. Tran-
scripts/metabolites significant below a false discovery rate
threshold of 60% were retained in each test set for OR analysis.
Each UniProt identifier in the ConsensusPathDB pathways can be
mapped to zero or more gene identifiers on the U133 chip. The
background estimate (m in equation 1) for OR analysis was
adjusted to reflect the following: 1) Where ConsensusPathDB
proteins could not be mapped to any gene identifiers, these were
ignored; and 2) where ConsensusPathDB proteins mapped to
multiple probesets measuring genes in the transcript data, the
number of probesets was used. In addition, several metabolites,
often referred to as ‘‘currency metabolites’’, which appear in many
pathways and do not provide specificity were removed before
analysis. The currency metabolites removed were phosphate,
diphosphate and NADP+. Thus, given the transcriptomic and
metabolomic data, an ‘‘effective size’’, Ni, could be defined for
each pathway, I, in terms of genes and metabolites, The effective
pathway size may be larger or smaller than the actual number of
proteins/metabolites in the pathway. Pathway significance was
calculated using the hypergeometric distribution,
pi~
X min(K,Ni)
j~ki
Ni
j
  
M{Ni
K{j
  
M
K
   ð1Þ
where K is the number of genes or metabolites associated with the
drug and ki is the number of genes or metabolites from the
pathway. P,0.05 was used as the criterion defining significance of
pathway enrichment.
Joint transcript and metabolite analysis
We used the pathway p-values pi from the individual analyses to
combine the data. If there were no transcripts or no metabolites
measured for pathway i, we set pi=1 for that data type. Since the
transcript/metabolite data were generated from separate experi-
ments. We thus assumed independence of the pathway associa-
tions from the different data sets. We thus computed the joint
probability pJi of association of pathway i with the drug sensitivity
phenotype as pJi=pGi pMi where pGi and pMi denote the probability
of association from the individual gene and metabolite data
separately.
Null models
Null model 1 was generated by creating random gene and
metabolite lists of matching size to those observed for each of the
drugs. Standard OR analysis was then performed and then
numbers of overlapping pathways were recorded. 100 sets of
random lists were generated and the mean number of pathways
common to different numbers of drugs were recorded in table 1.
Null model II assumes that the pathways are selected at
random, and so taking the numbers of pathways selected for each
drug, the exact probability of a pathway being selected for n drugs
was calculated. To do this we calculated the probability of a
pathway being selected at random from the full list of pathways,
given the number of pathways selected. By calculating this for each
of the drugs we have.
Additionally, we examined the added information given by the
joint analysis. For each drug the lists of p-values from the
metabolite and transcript analyses were randomly permuted 100
times before combination (randomizing the pathway association
between the two sets). The number of times in which more
pathways were significant (p,0.05) for the permuted lists than in
the real data was recorded.
Cumulative false discovery rates for all models were calculated
by dividing the ‘expected’ number of pathways as given by the null
model, by the actual (cumulative) number of pathways found in
the real data in at least n drugs.
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